One of the priority tasks of modern medicine is the search for new effective means of facilitating the treatment of injuries of various nature. Besides the stability, ease of use and prolonged action, the requirements for such compounds also include low toxicity. In this regard, copper-based complexes with high antioxidant activity are of particular interest. The aim of this work is to determine and compare the toxicity of bis[bis(3,5-dimethylpyrazol-1-yl)acetato]copper(II) complex, (Cu[HC(COO)(pzMe2)2]2 (complex 1) and Cu2(3,5-DIPS)4(H2O)3 (complex 2) by evaluating the survival, life expectancy and several blood parameters. According to the obtained data, complexes 1 and 2 proved to be low-toxic compounds. According to the test results: in case of complex 1 at a dose of 1450 mg/kg, we received a survival rate of 87,5%, and an average life expectancy of 26,8 days, and in the case of complex 2 at the same dose, the survival rate was 75% and the average life expectancy was 22,9 days, which indicates the low toxicity of these compounds (complex 2 has however a higher toxicity, since an identical result is achieved with a lower dose). Using the method of integration according to Behrens in experiments on rats, an average lethal dose of LD50/7 was found, which is more than 2000 mg/kg. Regarding the blood parameters: in case of complex 1, on the 3rd day of the experiment, an increase in the level of all studied blood parameters was observed. This was followed by a decrease, and on the 7th day there was a normalization of all blood parameters except for the number of platelets. Nevertheless, a trend towards normalization was observed in this indicator as well, which led to the normal value of platelet levels by the 21st day. When complex 2 was administered subcutaneously, a significant decrease in hemoglobin level was observed, which was restored by the 7th day; a significant decrease in blood clotting time (BCT), which persisted until the end of the study. By the 7th day, a significant decrease in the levels of platelets and erythrocytes was also noted. The results of haematological studies also confirmed the lowest toxicity of complex 1.
COMPARATIVE ANALYSIS OF TOXICITY OF BIS[BIS(3,5-DIMETHYLPYRAZOL-1-YL)ACETATO]COPPER AND Cu2(3,5-DIPS)4(H2O)3 COPPER(II)-BASED COMPLEXES
Santini, C;Pellei, M;
2022-01-01
Abstract
One of the priority tasks of modern medicine is the search for new effective means of facilitating the treatment of injuries of various nature. Besides the stability, ease of use and prolonged action, the requirements for such compounds also include low toxicity. In this regard, copper-based complexes with high antioxidant activity are of particular interest. The aim of this work is to determine and compare the toxicity of bis[bis(3,5-dimethylpyrazol-1-yl)acetato]copper(II) complex, (Cu[HC(COO)(pzMe2)2]2 (complex 1) and Cu2(3,5-DIPS)4(H2O)3 (complex 2) by evaluating the survival, life expectancy and several blood parameters. According to the obtained data, complexes 1 and 2 proved to be low-toxic compounds. According to the test results: in case of complex 1 at a dose of 1450 mg/kg, we received a survival rate of 87,5%, and an average life expectancy of 26,8 days, and in the case of complex 2 at the same dose, the survival rate was 75% and the average life expectancy was 22,9 days, which indicates the low toxicity of these compounds (complex 2 has however a higher toxicity, since an identical result is achieved with a lower dose). Using the method of integration according to Behrens in experiments on rats, an average lethal dose of LD50/7 was found, which is more than 2000 mg/kg. Regarding the blood parameters: in case of complex 1, on the 3rd day of the experiment, an increase in the level of all studied blood parameters was observed. This was followed by a decrease, and on the 7th day there was a normalization of all blood parameters except for the number of platelets. Nevertheless, a trend towards normalization was observed in this indicator as well, which led to the normal value of platelet levels by the 21st day. When complex 2 was administered subcutaneously, a significant decrease in hemoglobin level was observed, which was restored by the 7th day; a significant decrease in blood clotting time (BCT), which persisted until the end of the study. By the 7th day, a significant decrease in the levels of platelets and erythrocytes was also noted. The results of haematological studies also confirmed the lowest toxicity of complex 1.File | Dimensione | Formato | |
---|---|---|---|
Archiv euromedica, 12, 5 (2022) pp. 1-6.pdf
accesso aperto
Descrizione: Documento principale
Tipologia:
Versione Editoriale
Licenza:
PUBBLICO - Creative Commons
Dimensione
501.06 kB
Formato
Adobe PDF
|
501.06 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.